Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GFEIK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DAN-311
|
|||||
| Synonyms |
DAN311; DAN 311
Click to Show/Hide
|
|||||
| Organization |
Dantari
|
|||||
| Drug Status |
Clinical candidate
|
|||||
| Indication |
In total 1 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Clinical candidate
|
|||||
| Drug-to-Antibody Ratio |
60-70
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Camptothecin
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Targeted high-capacity drug conjugate platform.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.